Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique,
non-viral proprietary platform designed to deliver tumor suppressor genes to
cancer cells, today announced that, in a recent study, independent researchers
reported that TUSC2, a tumor suppressor gene and the active agent in Genprex’s
Oncoprex(TM) immunogene therapy, is a potential target and biomarker for
thyroid carcinoma. Genprex has no affiliation with these researchers. The
study, published in the International Journal of Molecular Sciences, reports
that TUSC2 overexpression decreased thyroid cancer proliferation, migration and
invasion. “We continue to be encouraged by data resulting from studies
conducted at multiple research institutions suggesting that TUSC2 may be an
effective treatment for many types of cancer, now including thyroid cancer,”
Genprex Chairman and Chief Executive Officer Rodney Varner said in the news
release.
To view the full press release, visit http://ibn.fm/X5uiL
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for cancer patients based
upon a unique proprietary technology platform. Genprex’s platform technologies
are designed to administer cancer-fighting genes by encapsulating them into
nanoscale hollow spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express proteins that are
missing or found in low quantities. The company’s lead product candidate,
Oncoprex(TM) immunogene therapy for non-small cell lung cancer (“NSCLC”), has a
multimodal mechanism of action whereby it has been shown to interrupt cell
signaling pathways that cause replication and proliferation of cancer cells,
re-establish pathways for apoptosis, or programmed cell death, in cancer cells,
and modulate the immune response against cancer cells. Oncoprex has also been
shown to block mechanisms that create drug resistance. In January 2020, the FDA
granted Fast Track Designation for Oncoprex(TM) imunogene therapy for NSCLC in
combination therapy with AstraZeneca’s Tagrisso(R). For more information,
please visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment